AstraZeneca reports positive results from PT003 Phase III PINNACLE trials in COPD
The Phase III program included two pivotal 24-week trials PINNACLE 1 and PINNACLE 2, which evaluated the potential of this fixed-dose combination. Glycopyrronium is a long-acting muscarinic antagonist
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.